Alx Oncology Holdings Inc (NASDAQ: ALXO)

Alx Oncology Holdings Inc is a clinical stage biotechnology company focused on developing novel therapies for cancer. The company's lead product candidate is evorpacept a CD47 blocking fusion protein designed to be used in combination with anti cancer antibodies. Its second candidate is ALX2004 an EGFR targeted antibody drug conjugate currently being evaluated in a first in human clinical trial. Alx Oncology Holdings Inc aims to advance these candidates through clinical development with the goal of providing new treatment options for patients with solid tumors and hematologic malignancies. The firm operates from its headquarters in the United States and relies on external partners for manufacturing and clinical trial execution.

Alx Oncology Holdings Inc generates revenue primarily through collaboration and licensing agreements with pharmaceutical and academic partners. These agreements typically involve upfront payments milestone payments and royalties on net sales of any future approved products. The company has a collaboration with Jazz Pharmaceuticals to develop evorpacept in combination with the HER2 targeted bispecific zanidatamab. Another collaboration with Sanofi focuses on evorpacept together with the CD38 targeted antibody isatuximab for the treatment of multiple myeloma. Alx Oncology Holdings Inc also works with MD Anderson Cancer Center on an investigator sponsored trial of evorpacept with rituximab for non Hodgkin lymphoma. The license agreement with Stanford University provides potential milestone payments and low single digit royalties on net sales of evorpacept and related products. The company anticipates that commercial scale manufacturing will be managed by contract manufacturing organizations.

Alx Oncology Holdings Inc positions itself as a developer of next generation immuno oncology therapies with a focus on CD47 blockade and EGFR targeting. The company's lead candidate evorpacept is designed to overcome the hematologic toxicities seen with other CD47 blocking agents that rely on an active Fc region. Evorpacept's inactive Fc domain aims to provide a broader therapeutic window and enable combination with a wide range of anti cancer antibodies chemotherapy and checkpoint inhibitors. The second candidate ALX2004 seeks to address limitations of earlier EGFR targeted antibody drug conjugate approaches by using a topoisomerase I inhibitor payload and a matuzumab derived antibody to reduce off tumor toxicity. Competitors in the CD47 space include Gilead Sciences through its acquisition of Forty Seven Pfizer through its acquisition of Trillium Therapeutics and various other biotechnology firms. In the EGFR targeted antibody drug conjugate arena competitors include AstraZeneca Daiichi Sankyo and several academic research programs. Alx Oncology Holdings Inc believes its differentiation lies in the engineered binding affinity of evorpacept the inactive Fc design and the payload selection of ALX2004 which together may provide improved efficacy and safety.

Alx Oncology Holdings Inc's eventual customers are expected to be patients receiving oncology treatment and the healthcare providers that administer those therapies. These include hospitals outpatient clinics and specialty cancer centers. The company also works with pharmaceutical partners through collaboration agreements which may become customers if its product candidates achieve regulatory approval. Revenue from product sales will depend on the ability to meet the needs of these patient populations and healthcare systems.